Treatment Recommendation for Metastatic High-Grade Pleomorphic Rhabdomyosarcoma in a 75-Year-Old Female
For this 75-year-old patient with metastatic pleomorphic rhabdomyosarcoma, I recommend palliative systemic therapy with doxorubicin-based chemotherapy as first-line treatment, with strong consideration for adding pembrolizumab based on emerging evidence showing objective responses in this specific histology.
Treatment Framework
Primary Treatment Approach
The management must be conducted at a sarcoma reference center with multidisciplinary expertise 1. Given the metastatic presentation, the treatment intent is palliative, with median survival typically 12-18 months from metastasis diagnosis 2.
First-line systemic therapy options:
- Doxorubicin monotherapy (standard adult soft tissue sarcoma approach) 1, 2
- Doxorubicin plus pembrolizumab combination - This is particularly compelling for pleomorphic rhabdomyosarcoma specifically, as a 2024 case series demonstrated objective responses with duration of 9-14 months in metastatic pleomorphic rhabdomyosarcoma, notably including patients with negative or low-positive PD-L1 status 3. This represents the most recent high-quality evidence specific to this exact histology and clinical scenario.
Alternative Chemotherapy Regimens
While pleomorphic rhabdomyosarcoma is treated as an adult-type high-grade sarcoma 1, there is evidence supporting pediatric-type multiagent protocols:
- VAC regimen (vincristine, actinomycin D, cyclophosphamide) showed impressive responses in a 70-year-old patient with metastatic pleomorphic rhabdomyosarcoma, achieving 16+ months without progression 4
- This approach challenges the conventional adult sarcoma treatment paradigm and should be considered, particularly if doxorubicin-based therapy fails
Age-Specific Considerations for This 75-Year-Old Patient
At age 75, treatment decisions must carefully balance:
- Cardiac function assessment is mandatory before doxorubicin (cumulative cardiotoxicity risk)
- Performance status will determine treatment intensity tolerance
- Symptom burden - if asymptomatic, disease stabilization rather than tumor shrinkage is an acceptable goal 2
- Consider that supportive care alone may be most appropriate if performance status is poor 2
Treatment Sequencing Algorithm
Step 1: Assess fitness for systemic therapy
- Good performance status → Proceed to Step 2
- Poor performance status → Early palliative care involvement, consider supportive care alone 2
Step 2: First-line systemic therapy
- Preferred: Doxorubicin + pembrolizumab (based on 3 showing specific efficacy in pleomorphic rhabdomyosarcoma)
- Alternative: Doxorubicin monotherapy (if immunotherapy contraindicated)
- Consider: VAC regimen if patient unsuitable for anthracyclines
Step 3: Second-line options upon progression
- Trabectedin (achieved complete response in one patient after doxorubicin/pembrolizumab 3)
- Alternative pediatric protocols (vincristine/irinotecan combinations 5)
Step 4: Local therapies for oligometastatic or symptomatic disease
- Stereotactic body radiotherapy (SBRT) for chemoresistant lung metastases - one case achieved complete response sustained >3 years 6
- Surgical metastasectomy for isolated resectable lesions
- Palliative radiotherapy for symptomatic bone metastases
- Bisphosphonates or denosumab for bone metastases 2
Critical Pitfalls to Avoid
Do not delay referral to sarcoma reference center - Management requires specialized multidisciplinary expertise 1, 2
Do not assume standard adult sarcoma protocols are optimal - Pleomorphic rhabdomyosarcoma may respond better to pediatric multiagent regimens than typical adult soft tissue sarcomas 4
Do not overlook immunotherapy - Despite variable PD-L1 status, pembrolizumab combined with doxorubicin showed objective responses specifically in pleomorphic rhabdomyosarcoma 3
Do not pursue aggressive treatment without assessing fitness - At age 75 with metastatic disease, quality of life must be prioritized; early palliative care involvement is essential 2
Do not ignore local treatment options - Even in metastatic disease, SBRT or surgery for oligometastatic sites can provide durable responses 6
Evidence Quality Assessment
The strongest recent evidence specific to metastatic pleomorphic rhabdomyosarcoma is the 2024 case series 3 demonstrating doxorubicin/pembrolizumab efficacy. While case series represent lower-level evidence than randomized trials, this is the most recent data directly addressing this exact clinical scenario. The 2025 UK guidelines 2 and 2021 ESMO guidelines 1 provide the framework for adult sarcoma management but lack specificity for pleomorphic rhabdomyosarcoma's unique biology.
The combination of doxorubicin plus pembrolizumab represents the most evidence-based approach for this specific histology in 2024-2025, provided the patient has adequate cardiac function and performance status to tolerate treatment.